Antibody array data showing activation of kinases in human red blood cells infected with the malaria parasite.
New research into malaria suggests targeting enzymes from the human host, rather than from the pathogen itself, could offer effective treatment for a range of infectious diseases, including COVID-19.
The study, conducted by an international team and led by RMIT University’s Professor Christian Doerig, outlines a strategy that could save years of drug discovery research and millions of dollars in drug development by repurposing existing treatments designed for other diseases such as cancer.
The approach shows so much promise it has received government funding for its potential application in the fight against COVID-19.
The study, published in Nature Communications, demonstrated that the parasites that cause malaria are heavily dependent on enzymes in red blood cells where the parasites hide and proliferate.
It also revealed that drugs developed for cancer, and which inactivate these human enzymes, known as protein kinases, are highly effective in killing the parasite and represent an alternative to drugs that target the parasite itself.
Lead author, RMIT’s Dr Jack Adderley, said the analysis revealed which of the host cell enzymes were activated during infection, revealing novel points of reliance of the parasite on its human host.
“This approach has the potential to considerably reduce the cost and accelerate the deployment of new and urgently needed antimalarials,” he said
“These host enzymes are in many instances the same as those activated in cancer cells, so we can now jump on the back of existing cancer drug discovery and look to repurpose a drug that is already available or close to completion of the drug development process.”
As well as enabling the repurposing of drugs, the approach is likely to reduce the emergence of drug resistance, as the pathogen cannot escape by simply mutating the target of the drug, as is the case for most currently available antimalarials.
Doerig, Associate Dean for the Biomedical Sciences Cluster at RMIT and senior author of the paper, said the findings were exciting, as drug resistance is one of the biggest challenges in modern healthcare, not only in the case of malaria, but with most infectious agents, including a large number of highly pathogenic bacterial species.
“We are at risk of returning to the pre-antibiotic era if we don’t solve this resistance problem, which constitutes a clear and present danger for global public health. We need innovative ways to address this issue,” he said.
“By targeting the host and not the pathogen itself, we remove the possibility for the pathogen to rapidly become resistant by mutating the target of the drug, as the target is made by the human host and not by the pathogen.”
Doerig’s team will now collaborate with the Peter Doherty Institute for Infection and Immunity (Doherty Institute) to investigate potential COVID-19 treatments using this approach, supported by funding from the Victorian Medical Research Acceleration Fund in partnership with the Bio Capital Impact Fund (BCIF).
Co-investigator on the grant, Royal Melbourne Hospital’s Dr Julian Druce, of the Victorian Infectious Diseases Reference Laboratory (VIDRL) at the Doherty Institute, was part of the team that were first to grow and share the virus that causes COVID-19, and said the research was an important contribution to efforts to defeat the pandemic.
Royal Melbourne Hospital’s Professor Peter Revill, Senior Medical Scientist at the Doherty Institute and a leader on Hepatitis B research, said the approach developed by the RMIT team was truly exciting.
“This has proven successful for other human pathogens including malaria and Hepatitis C virus, and there are now very real prospects to use it to discover novel drug targets for Hepatitis B and COVID-19,” he said.
The paper is the outcome of an RMIT-led international collaboration with researchers from Monash University in Melbourne, Dr Danny Wilson (University of Adelaide’s Malaria Biology Laboratory Head, The Hospital Research Foundation Fellow and Burnet Institute), Dr Jean-Philippe Semblat (from French Government agency Inserm, Paris) and Prof Oliver Billker (Umeå University, Sweden and Wellcome Sanger Institute, UK).
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Malaria discovery
- Last Chance
With only four ageing females left, under attack from invasive species on all sides and now trying to fight off avian malaria, Fatu Hiva Monarch is on the brink. Yet, thanks to the incredible ...
- Two studies identify new strategies for insect control
Mosquitoes spread several diseases, among them malaria and dengue virus. In 2020, about 241 million cases of malaria occurred worldwide, with a few more million cases occurring in 2021. Nearly half ...
- Studies identify new strategies for insect control
Mosquitoes spread several diseases, such as malaria and dengue. In 2020 about 241 million cases of malaria occurred worldwide, with a few more million cases occurring in 2021.
- The quest to find King Tut is detailed in new book about the storied pharaoh
Thirty centuries and more would pass before Tutankhamun’s name was heard again in the Valley of the Kings, after an American digger’s chance discovery of a few scraps of burial equipment,” writes ...
- 3-Dose Malaria Vaccine Shows Promise in African Trial
FRIDAY, Jan. 6, 2023 (HealthDay News) – New research has confirmed that a three-dose malaria vaccine is both safe and effective in West African adults, including those previously exposed to malaria.
Go deeper with Google Headlines on:
Malaria discovery
[google_news title=”” keyword=”malaria discovery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Targeting host enzymes to fight disease
- New medication offers new hope in fight against Alzheimer's
Pechlivanos also says this is not an end in fight against the disease. "Ultimately one day we hope for a cure. But that's probably far in the future," she said. Right now only Medicare recipients ...
- Discovery of Compound that Inhibits COVID and Colds
Researchers at the University of British Colombia’s Life Sciences Institute have identified a compound that can potentially halt infections associate | Clinical And Molecular Dx ...
- Research reveals cancer threat from virus protecting enzymes
A study by researchers from Weill Cornell Medicine revealed threat of cancer progression from enzymes which protect human cells against viruses.
- Recent Advancements in Treating HIV
HIV, the causative viral agent of AIDS, is a devasting and lethal disease that has caused widespread suffering worldwide for almost half a century. We still have no cure for this disease. While those ...
- Enzyme that defends human cells against viruses may be a potential target for future cancer treatments
The finding suggests that the enzyme may be a potential target for future cancer treatments ... of the enzyme called APOBEC3G in promoting the disease and found that it significantly increased ...
Go deeper with Google Headlines on:
Targeting host enzymes to fight disease
[google_news title=”” keyword=”targeting host enzymes to fight disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
